+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Duchenne Muscular Dystrophy Drugs Market - Global Forecast to 2030- Product Image
Duchenne Muscular Dystrophy Drugs Market - Global Forecast to 2030- Product Image
Sale

Duchenne Muscular Dystrophy Drugs Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967658
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Duchenne Muscular Dystrophy Drugs Market grew from USD 1.70 billion in 2024 to USD 1.85 billion in 2025. It is expected to continue growing at a CAGR of 8.65%, reaching USD 2.80 billion by 2030.

Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder, has long posed a formidable challenge for patients, caregivers, and healthcare systems. Characterized by relentless muscle degeneration and early loss of ambulatory function, the condition necessitates multidisciplinary management and innovative therapeutic solutions. Recent advances in molecular biology, genomics, and pharmacology have ushered in a new era of drug development, expanding treatment paradigms beyond corticosteroids to include exon skipping agents, gene therapy constructs, and stop codon read-through molecules. At the same time, evolving regulatory frameworks, shifting payer policies, and global trade factors are reshaping the commercial environment. This executive summary distills the most critical developments in the DMD treatment landscape, spotlighting groundbreaking scientific breakthroughs, market access dynamics, segmentation insights, and key regional and corporate strategies. By synthesizing these findings, this report equips decision-makers with actionable intelligence needed to navigate a rapidly transforming market and to align research, commercialization, and investment priorities with the ultimate goal of improving patient outcomes.

Transformative Shifts Redefining Drug Development and Patient Care

The DMD landscape is undergoing profound transformation fueled by technological leaps and collaborative ecosystems. Gene editing platforms, particularly CRISPR-based approaches, have migrated from proof-of-concept to early clinical validation, promising potential single-dose interventions that could alter disease trajectories. Concurrently, microdystrophin delivery via viral vectors is gaining traction as researchers optimize vector design, dosing regimens, and manufacturing scalability. Exon skipping agents have broadened their applicability with refined chemistries that enhance tissue penetration and reduce immunogenicity, while stop codon read-through molecules advance through late-stage trials, offering hope for specific mutation subpopulations.

Beyond modality innovation, a shift toward precision medicine is evident: biomarker-driven patient stratification, real-world evidence generation, and adaptive trial designs accelerate approval timelines and inform reimbursement discussions. Public-private partnerships and patient advocacy groups are catalyzing data sharing and risk-sharing agreements, smoothing the path from laboratory to clinic. These transformative shifts are redefining traditional drug development paradigms, underscoring the necessity for stakeholders to embrace agility, invest in novel platforms, and cultivate cross-sector collaborations.

Assessing the Cumulative Impact of United States Tariffs in 2025

In 2025, the United States implemented a series of tariffs on imported biopharmaceutical intermediates and delivery systems, directly influencing the cost structures of DMD therapies. Manufacturers reliant on ex-US raw materials for corticosteroids and vector production have faced increased production expenses, prompting restructuring of supply chains and strategic stockpiling initiatives. These tariffs have also affected the pricing negotiations with payers, as companies seek to preserve margins while maintaining patient access.

To mitigate cost pressures, organizations are localizing key processes-such as plasmid synthesis and viral vector packaging-within US-based facilities, absorbing initial capital expenditures to shield future pipeline assets from tariff volatility. Some players have diversified sourcing across North America, Europe, and Asia-Pacific to circumvent single-country dependencies. The cumulative impact of these trade measures has accelerated vertical integration strategies, compelling both established pharmaceutical firms and emerging biotech ventures to re-evaluate logistics, partner agreements, and production footprints. Ultimately, tariff-driven adjustments are reshaping competitive positioning, with companies that successfully balance cost containment and innovation securing stronger market resilience.

Key Segmentation Insights Guiding Strategic Prioritization

Insight into the DMD market trajectory emerges from multi-dimensional segmentation. Based on drug type, the market spans established corticosteroids, including both deflazacort formulations and prednisone variants, as well as exon skipping agents such as eteplirsen and golodirsen, gene therapies harnessing CRISPR and microdystrophin delivery, and stop codon read-through agents focused on ataluren. Patient demographics further refine focus, encompassing pediatric cohorts split into early-onset and late-onset groups, adolescent populations segmented into pre-teen and teen sub-cohorts, and adult segments covering young adults and middle-aged groups.

Channel dynamics reveal a distribution mix anchored by hospitals-from private specialty clinics to public institutions-augmented by online pharmacies via e-retail portals, manufacturers’ direct channels, third-party platforms, and traditional chain and independent retail outlets. End-user analysis differentiates healthcare professionals-from general practitioners to specialists and therapists-from caregivers supporting primary patients. Treatment approaches bifurcate into pharmacological interventions of both long-term and short-term regimens, alongside supportive therapies such as integrated occupational therapy and physiotherapy usage. Lastly, indications divide between disease progression delay, prioritizing muscle function maintenance, and symptomatic relief targeting inflammation control and pain management. This layered segmentation informs targeted development, pricing, and access strategies.

Key Regional Insights Across Major Global Markets

Regional markets exhibit distinct regulatory, reimbursement, and adoption environments. In the Americas, established health technology assessment frameworks and robust reimbursement channels favor rapid adoption of novel therapies, though pricing pressures and payer scrutiny demand compelling value propositions and strong real-world evidence. EMEA markets offer a heterogeneous mix: Western European countries provide centralized appraisal pathways and tenders with rigorous cost-effectiveness thresholds, while Middle Eastern and African regions show emerging interest, often facilitated through public-private collaborations and tiered pricing models.

Asia-Pacific landscapes range from advanced markets such as Japan and Australia-where expedited approvals and structured orphan drug incentives exist-to developing markets in Southeast Asia and South Asia, where access hinges on local production partnerships, licensing agreements, and capacity building for cold chain logistics. Across all regions, patient advocacy and clinician networks are critical in educating stakeholders, influencing policy decisions, and ensuring equitable distribution of emerging therapies.

Key Company Insights Driving Innovation and Competition

The competitive arena is populated by a blend of established pharma powerhouses and agile biotech innovators. Anuh Pharma Limited and Arlak Biotech have carved niches in corticosteroid formulations, while Aurigene and Bayer leverage integrated R&D platforms to advance exon skipping programs. Cipla and Enomark focus on cost-effective generics and localized manufacturing to address pricing constraints in emerging economies. Glasier Wellness, GlaxoSmithKline, and Johnson & Johnson bring deep pockets and global reach to late-stage gene therapy candidates, whereas Leo Pharma and Lifecare Neuro Products explore supportive therapy integrations.

Mankind Pharma, Merck & Co., and MODASA Pharmaceuticals drive research in stop codon read-through agents, collaborating with academic centers to refine ataluren analogues. Novartis and Pfizer marshal extensive gene editing consortia to accelerate CRISPR-based constructs, while QndQ Derma and RayBiotech target niche mutation subsets with specialized formulations. Ronyd Healthcare, Sarepta Therapeutics, and Sumitomo Corporation advance microdystrophin delivery, supported by Texas Pharmaceuticals and Wallace Pharmaceuticals in manufacturing scale-ups. Wellona Pharma and Zuventus Healthcare emphasize API innovation, rounding out a dynamic landscape where partnerships and licensing deals often dictate the pace of progress.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize the following actions to secure competitive advantage and accelerate impact:
  • Accelerate precision medicine approaches by investing in next-generation biomarkers and companion diagnostics, enabling targeted patient enrollment and stronger payer negotiations.
  • Diversify supply chains across multiple geographies, reducing exposure to tariff fluctuations and raw material constraints while fostering resilience through strategic stockpiling and local manufacturing hubs.
  • Deepen collaborations with patient advocacy groups and clinician networks to co-develop real-world evidence frameworks and value demonstration tools that satisfy stringent reimbursement criteria in key markets.
  • Expand adaptive trial designs in partnership with regulatory agencies, incorporating Bayesian models, seamless phase transitions, and patient-reported outcomes to optimize trial efficiency and reduce time to approval.
  • Forge public-private consortia to share infrastructure-such as vector production facilities and cold chain distribution networks-thereby lowering development costs and expediting market entry for complex biologics.

Conclusion: Seizing Opportunities in a Dynamic DMD Market

The DMD treatment landscape stands at an inflection point where scientific breakthroughs converge with evolving market dynamics. Gene therapy and exon skipping modalities promise to transcend symptomatic management, yet they bring new challenges in manufacturing scale, regulatory scrutiny, and cost containment. Tariff-driven supply chain shifts have underscored the need for strategic agility, while segmentation and regional insights highlight the importance of tailored commercialization strategies. Success will hinge on the ability to integrate precision medicine tools, forge collaborative ecosystems, and maintain robust evidence-generation pathways that resonate with payers and regulators. By aligning R&D investments with targeted patient subpopulations, optimizing distribution frameworks, and leveraging partnerships to share risk, industry participants can accelerate therapeutic innovation and drive sustainable growth.

Market Segmentation & Coverage

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Corticosteroids
    • Deflazacort Formulation
    • Prednisone Variant
  • Exon Skipping Agents
    • Eteplirsen Usage
    • Golodirsen Applications
  • Gene Therapy
    • CRISPR-Based Approaches
    • Microdystrophin Delivery
  • Stop Codon Read-Through Agents
    • Ataluren Formulation
  • Adolescent Patients
    • Pre-Teens Cohort
    • Teens Cohorts
  • Adult Patients
    • Middle-Aged Group
    • Young Adult Group
  • Pediatric Patients
    • Early-Onset Group
    • Late-Onset Group
  • Hospitals
    • Private Specialty Clinics
    • Public Institutions
  • Online Pharmacies
    • Healthcare eRetails
    • Manufacturers' Direct Portals
    • Third-Party Platforms
  • Retail Pharmacies
    • Chain Pharmacy Outlets
    • Independent Pharmacies
  • Healthcare Professionals
    • General Practitioners
    • Specialists
    • Therapists
  • Patients
    • Birth Caregivers
    • Primary Patients
  • Pharmacological Intervention
    • Long-Term Therapy
    • Short-Term Therapy
  • Supportive Therapy
    • Occupational Therapy Integrations
    • Physiotherapy Usage
  • Disease Progression Delay
    • Muscle Function Maintenance
  • Symptomatic Relief
    • Inflammation Control
    • Pain Management

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Anuh Pharma Limited
  • Arlak Biotech Pvt.Ltd.
  • Aurigene Pharmaceutical Services Ltd.
  • Bayer Pharmaceutical
  • Cipla Inc.
  • Enomark
  • Glasier Wellness, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Lifecare Neuro Products Limited
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.,
  • MODASA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • QndQ Derma
  • RayBiotech, Inc.
  • Ronyd Healthcare Pvt Ltd.
  • Sarepta Therapeutics, Inc.
  • Sumitomo Corporation
  • Texas Pharmaceuticals Pvt. Ltd.
  • Wallace Pharmaceuticals Pvt Ltd.
  • Wellona Pharma
  • Zuventus Healthcare Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Duchenne Muscular Dystrophy Drugs Market, by Drug Type
8.1. Introduction
8.2. Corticosteroids
8.2.1. Deflazacort Formulation
8.2.2. Prednisone Variant
8.3. Exon Skipping Agents
8.3.1. Eteplirsen Usage
8.3.2. Golodirsen Applications
8.4. Gene Therapy
8.4.1. CRISPR-Based Approaches
8.4.2. Microdystrophin Delivery
8.5. Stop Codon Read-Through Agents
8.5.1. Ataluren Formulation
9. Duchenne Muscular Dystrophy Drugs Market, by Patient Demographics
9.1. Introduction
9.2. Adolescent Patients
9.2.1. Pre-Teens Cohort
9.2.2. Teens Cohorts
9.3. Adult Patients
9.3.1. Middle-Aged Group
9.3.2. Young Adult Group
9.4. Pediatric Patients
9.4.1. Early-Onset Group
9.4.2. Late-Onset Group
10. Duchenne Muscular Dystrophy Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospitals
10.2.1. Private Specialty Clinics
10.2.2. Public Institutions
10.3. Online Pharmacies
10.3.1. Healthcare eRetails
10.3.2. Manufacturers' Direct Portals
10.3.3. Third-Party Platforms
10.4. Retail Pharmacies
10.4.1. Chain Pharmacy Outlets
10.4.2. Independent Pharmacies
11. Duchenne Muscular Dystrophy Drugs Market, by End-User
11.1. Introduction
11.2. Healthcare Professionals
11.2.1. General Practitioners
11.2.2. Specialists
11.2.3. Therapists
11.3. Patients
11.3.1. Birth Caregivers
11.3.2. Primary Patients
12. Duchenne Muscular Dystrophy Drugs Market, by Treatment Approach
12.1. Introduction
12.2. Pharmacological Intervention
12.2.1. Long-Term Therapy
12.2.2. Short-Term Therapy
12.3. Supportive Therapy
12.3.1. Occupational Therapy Integrations
12.3.2. Physiotherapy Usage
13. Duchenne Muscular Dystrophy Drugs Market, by Indication
13.1. Introduction
13.2. Disease Progression Delay
13.2.1. Muscle Function Maintenance
13.3. Symptomatic Relief
13.3.1. Inflammation Control
13.3.2. Pain Management
14. Americas Duchenne Muscular Dystrophy Drugs Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Anuh Pharma Limited
17.3.2. Arlak Biotech Pvt.Ltd.
17.3.3. Aurigene Pharmaceutical Services Ltd.
17.3.4. Bayer Pharmaceutical
17.3.5. Cipla Inc.
17.3.6. Enomark
17.3.7. Glasier Wellness, Inc.
17.3.8. GlaxoSmithKline PLC
17.3.9. Johnson & Johnson Services, Inc.
17.3.10. Leo Pharma
17.3.11. Lifecare Neuro Products Limited
17.3.12. Mankind Pharma Ltd.
17.3.13. Merck & Co., Inc.,
17.3.14. MODASA Pharmaceuticals Pvt. Ltd.
17.3.15. Novartis AG
17.3.16. Pfizer Inc.
17.3.17. QndQ Derma
17.3.18. RayBiotech, Inc.
17.3.19. Ronyd Healthcare Pvt Ltd.
17.3.20. Sarepta Therapeutics, Inc.
17.3.21. Sumitomo Corporation
17.3.22. Texas Pharmaceuticals Pvt. Ltd.
17.3.23. Wallace Pharmaceuticals Pvt Ltd.
17.3.24. Wellona Pharma
17.3.25. Zuventus Healthcare Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PREDNISONE VARIANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN USAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CRISPR-BASED APPROACHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY MICRODYSTROPHIN DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ATALUREN FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PRE-TEENS COHORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TEENS COHORTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY MIDDLE-AGED GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY YOUNG ADULT GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EARLY-ONSET GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY LATE-ONSET GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PRIVATE SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PUBLIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE ERETAILS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY MANUFACTURERS' DIRECT PORTALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CHAIN PHARMACY OUTLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENERAL PRACTITIONERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY THERAPISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY BIRTH CAREGIVERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PRIMARY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY OCCUPATIONAL THERAPY INTEGRATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHYSIOTHERAPY USAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY MUSCLE FUNCTION MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INFLAMMATION CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 143. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 145. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 146. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 147. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 148. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 149. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 150. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 151. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 152. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 156. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 158. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 159. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 160. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 161. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 162. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 164. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 165. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 166. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 169. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 177. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 178. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 181. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 182. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 183. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 184. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 186. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 255. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 256. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 257. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 258. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 259. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 260. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 262. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 263. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 264. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 266. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 267. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 268. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, 2018-2030 (USD MILLION)
TABLE 270. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENTS, 2018-2030 (USD MILLION)
TABLE 271. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 272. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PHARMACOLOGICAL INTERVENTION, 2018-2030 (USD MILLION)
TABLE 273. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 274. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 275. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISEASE PROGRESSION DELAY, 2018-2030 (USD MILLION)
TABLE 276. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SYMPTOMATIC RELIEF, 2018-2030 (USD MILLION)
TABLE 277. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 279. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING AGENTS, 2018-2030 (USD MILLION)
TABLE 280. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 281. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STOP CODON READ-THROUGH AGENTS, 2018-2030 (USD MILLION)
TABLE 282. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 283. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADOLESCENT PATIENTS, 2018-2030 (USD MILLION)
TABLE 284. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 285. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 286. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMA

Companies Mentioned

  • Anuh Pharma Limited
  • Arlak Biotech Pvt.Ltd.
  • Aurigene Pharmaceutical Services Ltd.
  • Bayer Pharmaceutical
  • Cipla Inc.
  • Enomark
  • Glasier Wellness, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Lifecare Neuro Products Limited
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.,
  • MODASA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • QndQ Derma
  • RayBiotech, Inc.
  • Ronyd Healthcare Pvt Ltd.
  • Sarepta Therapeutics, Inc.
  • Sumitomo Corporation
  • Texas Pharmaceuticals Pvt. Ltd.
  • Wallace Pharmaceuticals Pvt Ltd.
  • Wellona Pharma
  • Zuventus Healthcare Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report - Product Image

Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report

  • Report
  • 220 Pages
  • Global
From
Duchenne Muscular Dystrophy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Duchenne Muscular Dystrophy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 172 Pages
  • Global
From
Duchenne Muscular Dystrophy Drugs Market by Product Type, Therapeutic Approach, End User, and Region 2025-2033 - Product Image

Duchenne Muscular Dystrophy Drugs Market by Product Type, Therapeutic Approach, End User, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From
Duchenne Muscular Dystrophy Market Report 2025 - Product Image

Duchenne Muscular Dystrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Duchenne Muscular Dystrophy Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Duchenne Muscular Dystrophy Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From

About the Duchenne Muscular Dystrophy Drug Market

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that affects the muscles and is caused by a mutation in the dystrophin gene. It is the most common form of muscular dystrophy and is characterized by progressive muscle weakness and loss of muscle mass. Treatment for DMD is limited to supportive care and the use of certain drugs to slow the progression of the disease. Central Nervous System (CNS) drugs are used to treat the symptoms of DMD, such as muscle spasms, pain, and fatigue. These drugs can also help to improve the quality of life of those affected by the disorder. The DMD drug market is a rapidly growing segment of the CNS drug market. It is estimated that the global DMD drug market will reach $2.5 billion by 2027, driven by the increasing prevalence of DMD and the development of new drugs. Several companies are involved in the development and commercialization of DMD drugs, including Sarepta Therapeutics, Pfizer, GlaxoSmithKline, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.